ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,089Medicare Part D Prescriptions Filled, Including Refills

Rank: 488 out of 2343

$309K Total Retail Price of All Prescriptions

Rank: 1193 out of 2343

327 Patients Receiving at Least One Drug in Part D
62%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 327 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

4% of this provider’s 6,851 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$31 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

31 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
OMEPRAZOLE 731 463 1 4
SIMVASTATIN 537 380 2 1
AMLODIPINE BESYLATE 480 389 3 5
TRAMADOL HCL 406 263 4 25
ENALAPRIL-HYDROCHLOROTHIAZIDE 346 282 10 5 299
LEVOTHYROXINE SODIUM 309 212 6 2
METOPROLOL TARTRATE 262 203 7 7
METFORMIN HCL 258 185 8 9
AZITHROMYCIN 255 146 9 39
VENTOLIN HFA 232 138 10 79
LOSARTAN-HYDROCHLOROTHIAZIDE 220 188 11 64
GLYBURIDE-METFORMIN HCL 207 162 R 12 154
PRAVASTATIN SODIUM 204 184 13 15
GABAPENTIN 198 143 14 16
NAPROXEN SODIUM 169 92 15 408
BETAMETHASONE DIPROPIONATE 157 81 16 284
LOSARTAN POTASSIUM 151 86 17 19
LISINOPRIL 150 88 18 3
ENALAPRIL MALEATE 126 70 19 58
CLOTRIMAZOLE-BETAMETHASONE 123 72 20 127
ISOSORBIDE MONONITRATE ER 122 95 21 32
HUMULIN 70-30 114 63 22 243
FUROSEMIDE 114 94 22 6
CYCLOBENZAPRINE HCL 113 46 R 24 109
GLIPIZIDE 110 50 25 56
CIPROFLOXACIN HCL 107 63 26 72
IBUPROFEN 105 80 27 75
FAMOTIDINE 99 71 28 60
ATORVASTATIN CALCIUM 95 66 29 10
MECLIZINE HCL 93 81 30 103
INSULIN SYRINGE 92 58 31 102
BACLOFEN 89 60 32 161
ADVAIR DISKUS 87 36 33 34
LANTUS 82 64 34 51
JANUVIA 79 59 35 50
ACETAMINOPHEN-CODEINE 78 54 S3 36 112
CARVEDILOL 77 48 37 27
DIOVAN HCT 73 54 38 63
DONEPEZIL HCL 71 56 39 21
CLONIDINE HCL 70 44 40 70
CLOPIDOGREL 67 49 41 26
ENDOCET 59 58 S2 42 97
MUPIROCIN 56 29 43 260
SINGULAIR 54 32 44 100
LACTULOSE 52 33 45 139
ATENOLOL 51 29 46 12
LIDOCAINE 51 41 46 258
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 13, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.